Unmet Need: Method for modulating immune response with ligands for natural killer T cells. A great diversity of lipids and glycolipids have been shown to bind to the various isoforms of CD1 and activate natural killer T cells. This technology describes a series of novel compounds that have been identified to act as ligands for natural killer T cells and modulate the immune response of these cells.
This technology is a tri-specific antibody targeting multiple epitopes of the human immunodeficiency virus (HIV) for immunotherapy against HIV infection and prevention of viral transmission. Unmet Need: Multiple epitope specific antibody for treatment of HIV. Alternatives in development include antibody therapy applied biannually, including monoclonal and bispecific antibodies which may also decrease the reservoir of infected T cells.
Drug screening for AIDS and cancer therapeutics. The Technology: Easy-to-handle CD4+ human cancer cell line for AIDS research. More studies are needed to dissect the mechanisms by which CD4 antigen contributes to AIDS virus infection.